Entera Bio Ltd.
ENTX Healthcare Biotechnology
Entera Bio Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42,000.00, down 76.8% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS fell 133.3% and free cash flow fell 108.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ENTX
Entera Bio Ltd. (ENTX) Piotroski F-score
Entera Bio Ltd.'s Piotroski F-score for fiscal 2025 cannot be worked out: needs three fiscal years.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2022 | 4 | (2.00) |
| FY2021 | 6 | 1.00 |
| FY2020 | 5 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (90.13%) | — | Fail | 0 |
| Positive operating cash flow | (7.37m) | (6.82m) | Fail | 0 |
| Rising return on assets | (90.13%) | — | n/a | — |
| Cash flow above net income | 4.07m | 2.72m | Pass | 1 |
| Falling long-term leverage | 0.00 | — | n/a | — |
| Rising current ratio | 6.94 | 7.63 | Fail | 0 |
| No new shares issued | 46,191,000 | 37,650,000 | Fail | 0 |
| Rising gross margin | — | 4.97% | n/a | — |
| Rising asset turnover | 0.00 | — | n/a | — |
| Piotroski F-score | n/a — needs three fiscal years | — | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| CAPR Capricor Therapeutics, Inc. compare | 4 |
| ASMB Assembly Biosciences, Inc. compare | 4 |
| PRTA Prothena Corporation plc compare | 2 |
| EDIT Editas Medicine, Inc. compare | 2 |
| ENTX Entera Bio Ltd. | — |
| DMAC DiaMedica Therapeutics, Inc. compare | — |
| TECX Tectonic Therapeutic, Inc. compare | — |
| YDES YD Bio Limited compare | — |
| RZLT Rezolute, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover